MSEsperanza
Senior Member (Voting Rights)
Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome—a case series of standardized individual experimental therapy
Research letter / case series of 10 patients.
Announced English version not published yet.
So in lieu of an abstract here's a google translate link for now.
Google translate:
A relevant proportion of patients suffer from fatigue-dominant long/post-COVID syndrome after SARS-CoV-2 infection. Elevated levels of autoantibodies (AAK) against G protein-coupled neurotransmitter receptors (including β-adrenergic and muscarinic) were detected in 57% of those affected by long-term/post-COVID treatment at university ( 1 ) .
In patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the reduction of β-adrenergic AAK by means of immunoadsorption was associated with clinical improvement ( 2).
Reports on individual treatment successes with apheresis procedures for long-/post-COVID are increasingly being propagated via social media. However, cases or studies with negative results receive the necessary attention much less frequently. In view of the insufficient overall data available to date, professional societies are calling for a broader scientific basis, to which we would like to contribute with this case series.
[...]
From the results section:
[...] In the follow-up, the GPCR-AAK were still lower than the baseline level, but were mostly detectable again above the reference value (β 1 [8/10 study participants], β 2 [9/10], M 3 [7/10] and M 4[6/10]).
At the same time, no clinically relevant change in mental and physical health compared to the initial findings could be determined either after the immune adsorption cycle or during follow-up (Table) . The health-related quality of life (EQ-5D) and subjective satisfaction of the study participants improved marginally at best (table) .
Citation:
Ruhe J, Giszas B, Schlosser M, Reuken PA, Wolf G, Stallmach A: Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome—a case series of standardized individual experimental therapy. Dtsch Arztebl Int 2023; 120. DOI: 10.3238/arztebl.m2023.0073
Link to the German full text here.
Research letter / case series of 10 patients.
Announced English version not published yet.
So in lieu of an abstract here's a google translate link for now.
Google translate:
A relevant proportion of patients suffer from fatigue-dominant long/post-COVID syndrome after SARS-CoV-2 infection. Elevated levels of autoantibodies (AAK) against G protein-coupled neurotransmitter receptors (including β-adrenergic and muscarinic) were detected in 57% of those affected by long-term/post-COVID treatment at university ( 1 ) .
In patients with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), the reduction of β-adrenergic AAK by means of immunoadsorption was associated with clinical improvement ( 2).
Reports on individual treatment successes with apheresis procedures for long-/post-COVID are increasingly being propagated via social media. However, cases or studies with negative results receive the necessary attention much less frequently. In view of the insufficient overall data available to date, professional societies are calling for a broader scientific basis, to which we would like to contribute with this case series.
[...]
From the results section:
[...] In the follow-up, the GPCR-AAK were still lower than the baseline level, but were mostly detectable again above the reference value (β 1 [8/10 study participants], β 2 [9/10], M 3 [7/10] and M 4[6/10]).
At the same time, no clinically relevant change in mental and physical health compared to the initial findings could be determined either after the immune adsorption cycle or during follow-up (Table) . The health-related quality of life (EQ-5D) and subjective satisfaction of the study participants improved marginally at best (table) .
Citation:
Ruhe J, Giszas B, Schlosser M, Reuken PA, Wolf G, Stallmach A: Immune adsorption for the treatment of fatigue-dominant long-/post-COVID syndrome—a case series of standardized individual experimental therapy. Dtsch Arztebl Int 2023; 120. DOI: 10.3238/arztebl.m2023.0073
Link to the German full text here.
Last edited:
